8 Most Experienced CAR-T Therapy Hospitals with Best Success Rates in 2026

Introduction

For patients with relapsed or refractory blood cancers in India, hope once meant a flight abroad and a cost that exceeded a lifetime's savings. That equation changed decisively when India's drug regulator approved the country's first indigenous CAR-T cell therapy in October 2023. NexCAR19, developed by an IIT Bombay and Tata Memorial Centre partnership, brought the promise of engineered immune cells within reach at a fraction of Western prices. But access alone is not enough.

The therapy's success depends heavily on the hospital's experience in managing every step, from patient selection and bridging therapy to apheresis coordination, infusion timing, and the critical management of cytokine release syndrome (CRS) and neurotoxicity. Patients now face a new question: which Indian centre has the documented volume and clinical infrastructure to turn this powerful therapy into a durable remission. This article ranks the institutions that have built that capability, so you can make an informed, time-sensitive decision.

Key Takeaways

Before examining individual centres, review these distilled findings drawn from clinical trial data, regulatory announcements, and institutional reporting. They establish the benchmark for evaluating CAR-T success in India today.

• Indigenous CAR-T efficacy: In NexCAR19 clinical trials among 64 patients, 67% achieved an objective response, and about half had a complete response.

• Top Indian institutions by volume: Tata Memorial Centre in Mumbai and AIIMS in New Delhi are the highest-volume centres for indigenous CAR-T infusions, directly linking procedure count to safety outcomes.

• Global reference point: A Dana-Farber-led study that changed FDA guidelines for CNS lymphoma reported an 89% overall response rate and 67% complete response rate, framing the upper boundary of this therapy’s potential.

• Core outcome measures: When a hospital cites success, clarify whether it means objective response rate (tumor shrinkage), complete response (cancer disappearance), or progression-free survival (durability of the response).

• Indian cost benchmark: NexCAR19 starts in the range of ₹30 to 40 lakh, a stark contrast to Western CAR-T costs that can exceed ₹5 crore.

1. Pi Cancer Care Hyderabad: India's Comprehensive CAR-T Referral and Recovery Coordination Hub

A CAR-T cell therapy journey in India spans weeks of coordination across different cities, hospital teams, and lab networks. Pi Cancer Care Hyderabad fills the gap between the infusion itself and everything that must happen to get you there safely. The hub model picks the right infusion centre for your specific diagnosis and manages the logistics through to post-discharge recovery.

Pi Cancer Care does not itself perform the CAR-T infusion. The model focuses on getting you infused at the centre best suited to your disease and keeping you on track during the high-risk weeks of manufacturing and recovery.

2. Tata Memorial Centre, Mumbai: The Pioneer of NexCAR19 Clinical Trials and Indigenous Therapy

Tata Memorial Centre (TMC) in Mumbai is the foundational site where India’s CAR-T era began. It conducted the first patient infusion in June 2021 and led the phase 1/2 clinical trials that established the safety and efficacy benchmarks for NexCAR19, India’s first indigenously Made-in-India CAR-T therapy. When you evaluate a hospital’s claim of CAR-T expertise, TMC’s clinical infrastructure is the reference standard against which others are measured. Here is the evidence chain underpinning that position:

1. Trial data defines the baseline: TMC’s published results in 64 patients showed a 67% objective response rate, with cancer disappearing completely in roughly half. These are the numbers your doctor will quote when discussing likely outcomes.

2. Highest procedure volume in India: No other centre has infused more patients with indigenous CAR-T cells. Volume directly correlates with a clinical team’s ability to detect and manage early CRS and neurotoxicity before they escalate.

3. Integrated on-site critical care: The centre maintains on-site access to a dedicated haematology ICU, tocilizumab, and neurologic consults. In CAR-T therapy, having these resources physically inside the same building, not on-call from a different wing, alters the speed of toxicity intervention.

3. All India Institute of Medical Sciences (AIIMS), New Delhi: High-Volume Centre for Lymphoma and Leukaemia CAR-T

AIIMS New Delhi treats more CAR-T patients under a public-funded model than any other centre in India, but public-sector affordability carries the weight of patient load. Consider these factors when evaluating a slot there:

1. High-volume safety advantage: Its haematology department handles a relentless caseload of B-ALL and DLBCL in both children and adults. High-volume CAR-T centres achieve measurably safer outcomes because their multidisciplinary teams have standardised CRS and ICANS management, and they see rare toxicity presentations often enough to handle them as protocol steps, not panicked exceptions.

2. Cost accessibility: As a public hospital, its infrastructure keeps procedural markups lower, and several central government health schemes recognise treatment at AIIMS. India's homegrown CAR-T therapy still starts at ₹30 to 40 lakh, so that public-sector pricing difference can decide whether a family can afford treatment.

3. Wait-time risk: Securing a CAR-T slot means navigating a scheduling queue. For a patient with aggressive, fast-moving disease, that queue can shift from an inconvenience to a clinical risk. In those cases you weigh AIIMS's volume and safety advantage against the real bridging challenge: keeping the cancer under control while the slot clears.

4. Apollo Hospitals, Chennai: Advanced Commercial CAR-T Access with Multispecialty Critical Care

Apollo Hospitals in Chennai holds a distinct position in the Indian CAR-T landscape by combining commercial access to NexCAR19 through ImmunoACT's distribution network with a multispecialty hospital infrastructure designed for high-acuity complications. In CAR-T therapy, the defining resource is 24/7 neurology coverage capable of grading immune effector cell-associated neurotoxicity syndrome (ICANS) in real time and initiating the correct intervention. Apollo's model integrates neurology, haematology, and critical care into a single on-site unit, a structure that mirrors the toxicity management protocols used in high-volume US CAR-T centres.

Apollo's patient pathway runs on a standardized, full-cycle protocol. It begins with a rigorous selection screening to stratify disease burden and performance status, moves through a structured bridging therapy window during the apheresis and manufacturing period, and progresses to inpatient infusion with a predetermined monitoring schedule. The hospital has documented its infusion protocols clearly, which matters because CAR-T complications are front-loaded. A centre that does not have a written, team-wide escalation pathway for grade 3 or 4 CRS is operating without the playbook that high-volume centres consider non-negotiable.

The consideration is cost transparency. Commercial treatment at a private multispecialty hospital carries pricing that includes critical care ancillaries beyond the cost of the drug product. Request an itemised estimate that separates the NexCAR19 drug price, apheresis charges, and infusion admission fees. Apollo's model can deliver faster infusion scheduling than a public hospital queue, but you need a hard financial picture early in the decision process.

5. Christian Medical College (CMC), Vellore: Integrated Haematology Expertise for Paediatric and Adult CAR-T

CMC Vellore integrates CAR-T capability onto a foundational platform of decades-long bone marrow transplant (BMT) volume. This matters for two specific cohorts: high-risk paediatric ALL patients and adolescents and young adults with multiply relapsed lymphoma. Here is how the model breaks down:

• BMT-to-CAR-T continuity: CMC's established transplant registry and infection control standards form the institutional backbone for CAR-T toxicity monitoring. The centre has built rigorous post-BMT infection surveillance over decades. That same infrastructure maps directly onto the demands of post-CAR-T monitoring.

• Paediatric and adolescent protocol depth: CMC handles complex paediatric haematological malignancies that frequently require travel from across India. The multidisciplinary tumour board brings together paediatric haematology, neuro-oncology, and infectious disease specialists before treatment starts, a structure that adapts well to CAR-T for younger patients, where neurotoxicity presentation patterns differ from adults.

• Long-term follow-up infrastructure: Durability data matters. CMC's patient registries and documented follow-up pathways allow systematic tracking of progression-free survival and late toxicity, turning a centre's claim of "good results" into auditable, time-bound outcomes.

Families weighing CMC should confirm how many specific paediatric CAR-T infusions the centre has completed, and whether its bridging protocols are adapted to the age and disease aggressiveness of the child.

6. Dana-Farber Cancer Institute, Boston: Global Benchmark Defining CNS Lymphoma CAR-T Success Standards

Dana-Farber Cancer Institute in Boston holds a unique clinical reference value even for patients being treated in India. Its landmark study on axicabtagene ciloleucel (Yescarta) in primary CNS lymphoma produced data so compelling that it drove a February 2026 FDA label update removing the prior exclusion of CNS lymphoma patients from CAR-T eligibility. The numbers that changed a global regulatory standard: an 89% overall response rate and 67% complete response rate, with a median progression-free survival of 14.3 months.

This data matters for your decision-making because it sets the efficacy ceiling against which Indian centre outcomes should be contextualized. When a hospital in India quotes its response rates, you need to know whether the patient population includes CNS lymphoma, a far more challenging subtype, or primarily systemic lymphoma and leukaemia. The Indian clinical trials for NexCAR19 did not focus on CNS lymphoma, so a direct percentage comparison would be statistically invalid.

Use Dana-Farber’s data as a benchmark, not a comparison target. It represents outcomes at the world’s most resource-intensive centre for a narrowly defined, high-risk population. The right question for your Indian centre is different: not “do you match the US numbers?” but rather “what are your outcomes for my exact subtype, and how do your supportive care protocols compare to the published global standard?”

7. How CAR-T Success Rates Are Actually Measured and Which Factors Influence Outcomes

When a hospital says it has a "high success rate," you need to ask which specific metric it is quoting. Success rates in CAR-T are measured using three standard terms:

• Objective response rate (ORR): the proportion of patients whose cancer shrinks measurably

• Complete response (CR): the cancer has disappeared on scans

• Progression-free survival (PFS): tracks the time until the cancer starts growing again, the most patient-relevant measure in everyday clinical conversations

Outcomes can differ sharply depending on four modifiable factors:

• Disease burden at infusion: The strongest predictor; a patient with bulky, rapidly progressing disease at the time of CAR-T infusion will almost certainly have a lower CR rate than one who received effective bridging therapy to bring the disease under control first

• Tumour subtype: CAR-T performs differently in B-ALL, DLBCL, and mantle cell lymphoma

• Prior lines of treatment: Heavily pretreated patients may have exhausted T-cells that manufacture poorly

• Performance status: A standardised measure of how active and functional you are predicts how well you will tolerate the CRS and neurotoxicity that accompany a strong anti-tumour response

8. How Much CAR-T Cell Therapy Costs in India in 2026 and Available Financial Support

In 2026, an indigenous CAR-T infusion with NexCAR19 starts in the range of ₹30 to 40 lakh, but that figure represents just the therapy product. You must add hospital admission charges, apheresis collection, bridging therapy, and ICU contingency costs to build a complete budget. Compare the economics:

• Global comparison: US-approved CAR-T drugs such as Kymriah and Yescarta can cost ₹5 crore per patient and go up to ₹10 crore, including hospital expenses. The Indian government’s investment of ₹18.96 crore through NBM-BIRAC for the clinical trials is one reason this domestic pricing was possible

• Future cost reduction: The development team is actively working to push costs still lower, with stated aims of reducing the therapy cost down to ₹20 lakh, though this remains a research-stage goal as of 2026

• Financial support mechanisms: Central schemes like PMJAY and state-level Chief Minister’s relief funds have begun to include provisions for high-cost oncology therapies, though coverage for NexCAR19 requires a case-by-case verification. Manufacturer patient assistance programs through ImmunoACT are available for eligible patients, and several private insurance providers now list CAR-T as a reimbursable procedure, but confirm policy wording directly with your insurer before starting apheresis

Conclusion

India’s CAR-T therapy landscape in 2026 is defined by Tata Memorial Centre’s clinical trial leadership, AIIMS’s public-sector volume, Apollo’s commercial critical-care integration, and CMC Vellore’s paediatric depth. Pi Cancer Care is the only entity providing cross-centre coordination that fills the logistical and recovery gaps left uncovered between these institutions. Procedure volume and documented toxicity management protocols remain the most reliable predictors of outcome, far more than institutional brand recognition.

Evaluate any centre by its specific response rates for your exact blood cancer subtype, its written protocol for CRS and ICANS management, and its ability to start you on the right bridging therapy while your engineered cells are manufactured.

With indigenous pricing at a tenth of Western costs and growing institutional expertise, Indian centres now deliver globally comparable CAR-T outcomes. The critical step is matching your specific disease to the centre best structured to treat it.

Frequently Asked Questions

Which hospitals in India perform the most CAR-T cell therapy procedures and have the highest success rates?

Tata Memorial Centre in Mumbai is India's highest-volume CAR-T centre, having conducted the first NexCAR19 infusion and led the phase 1/2 trials. AIIMS New Delhi follows as the primary public-sector high-volume site. Success rates at TMC show a 67% objective response rate and approximately 50% complete response rate across trial patients.

What does success rate in CAR-T therapy actually measure, and what factors affect these outcomes?

Success rate measures are defined by three specific metrics:

• Objective response (ORR): tumor shrinkage

• Complete response (CR): cancer disappearance

• Progression-free survival (PFS): time until cancer returns

The strongest factors affecting outcomes are:

• Disease burden at infusion: The strongest predictor

• Tumour subtype: CAR-T performs differently across subtypes

• Prior lines of treatment: Heavily pretreated patients may have exhausted T-cells

• Patient performance status: Predicts tolerance of CRS and neurotoxicity

Always ask a centre which specific metric they are quoting.

How much does CAR-T cell therapy cost in India in 2026, and what financial support or schemes are available?

NexCAR19 costs approximately ₹30 to 40 lakh for the drug product, with hospital charges added separately. This compares to ₹5 to 10 crore for US CAR-T products. Financial support includes PMJAY coverage (case-specific), manufacturer patient assistance programs through ImmunoACT, and some private insurance policies. Confirm coverage directly with your insurer before apheresis begins.

How can patients in India find and choose a genuinely experienced CAR-T therapy centre for their specific blood cancer?

Ask each centre for its volume of CAR-T infusions in the last 12 months and its response rates for your exact blood cancer subtype. Look for documented, team-wide toxicity management protocols. A coordination hub like Pi Cancer Care can match your subtype and disease burden to the most experienced centre, then manage the apheresis scheduling, manufacturing timeline, and post-infusion monitoring.

What questions should a patient or family ask a hospital when evaluating its CAR-T cell therapy programme?

Ask: how many CAR-T infusions has this centre performed in the last 12 months? What are your response and survival rates for my specific cancer subtype? What is your written protocol for managing CRS and neurotoxicity?

Do you have tocilizumab and ICU capabilities on-site? What bridging therapy approach do you recommend before apheresis? Who coordinates my recovery monitoring after discharge?

Sources

1. India’s First Homegrown CAR T-Cell Therapy - NCI - www.cancer.gov

2. Advanced Centre for Treatment Research & Education in Cancer | CAR T-cell therapy trials for cancer treatment begin in Mumbai - actrec.gov.in

3. World's most Affordable CAR-T therapy, NexCAR19, puts ... - www.pib.gov.in